Credit Agricole’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $700M | Buy |
3,694,158
+716,592
| +24% | +$135M | 1.42% | 13 |
|
|
2026
Q1 | $587M | Buy |
2,977,566
+2,955,212
| +13,220% | +$570M | 1.54% | 12 |
|
|
2025
Q4 | $4.11M | Buy |
22,354
+11,354
| +103% | +$1.99M | 0.01% | 654 |
|
|
2025
Q3 | $1.69M | Buy |
+11,000
| New | +$1.66M | ﹤0.01% | 838 |
|
|
2025
Q1 | $1.26M | Sell |
8,568
-624
| -7% | -$90.3K | ﹤0.01% | 853 |
|
|
2024
Q4 | $1.2M | Buy |
9,192
+1,477
| +19% | +$207K | ﹤0.01% | 881 |
|
|
2024
Q3 | $1.2M | Buy |
7,715
+5,830
| +309% | +$941K | 0.01% | 739 |
|
|
2024
Q2 | $294K | Hold |
1,885
| – | – | ﹤0.01% | 894 |
|
|
2024
Q1 | $258K | Buy |
1,885
+385
| +26% | +$51K | ﹤0.01% | 716 |
|
|
2023
Q4 | $202K | Sell |
1,500
-500
| -25% | -$65K | ﹤0.01% | 705 |
|
|
2023
Q3 | $271K | Buy |
2,000
+500
| +33% | +$68.3K | ﹤0.01% | 519 |
|
|
2023
Q2 | $215K | Hold |
1,500
| – | – | ﹤0.01% | 419 |
|
|
2023
Q1 | $208K | Sell |
1,500
-500
| -25% | -$67.3K | ﹤0.01% | 389 |
|
|
2022
Q4 | $271K | Hold |
2,000
| – | – | 0.01% | 395 |
|
|
2022
Q3 | $220K | Hold |
2,000
| – | – | ﹤0.01% | 392 |
|
|
2022
Q2 | $264K | Hold |
2,000
| – | – | 0.01% | 379 |
|
|
2022
Q1 | $265K | Hold |
2,000
| – | – | ﹤0.01% | 393 |
|
|
2021
Q4 | $233K | Sell |
2,000
-765
| -28% | -$90K | ﹤0.01% | 400 |
|
|
2021
Q3 | $332K | Buy |
2,765
+765
| +38% | +$89.1K | 0.01% | 347 |
|
|
2021
Q2 | $240K | Sell |
2,000
-100
| -5% | -$11K | ﹤0.01% | 338 |
|
|
2021
Q1 | $209K | Sell |
2,100
-1,185
| -36% | -$119K | 0.01% | 329 |
|
|
2020
Q4 | $328K | Buy |
+3,285
| New | +$348K | 0.01% | 282 |
|
|
2017
Q4 | – | Sell |
-2,000
| Closed | -$136K | – | 436 |
|
|
2017
Q3 | $136K | Hold |
2,000
| – | – | ﹤0.01% | 1332 |
|
|
2017
Q2 | $136K | Buy |
2,000
+1,000
| +100% | +$65.3K | ﹤0.01% | 1339 |
|
|
2017
Q1 | $62K | Hold |
1,000
| – | – | ﹤0.01% | 1579 |
|
|
2016
Q4 | $55K | Hold |
1,000
| – | – | ﹤0.01% | 1410 |
|
|
2016
Q3 | $66K | Buy |
+1,000
| New | +$65.4K | ﹤0.01% | 1537 |
|
|
2015
Q1 | – | Sell |
-1,480
| Closed | -$101K | – | 1470 |
|
|
2014
Q4 | $101K | Sell |
1,480
-3,256
| -69% | -$233K | ﹤0.01% | 1457 |
|
|
2014
Q3 | $339K | Buy |
4,736
+3,256
| +220% | +$238K | ﹤0.01% | 1282 |
|
|
2014
Q2 | $110K | Buy |
1,480
+304
| +26% | +$22K | ﹤0.01% | 1458 |
|
|
2014
Q1 | $76K | Buy |
+1,176
| New | +$76K | ﹤0.01% | 1397 |
|
Other funds holding AZN
EP
IA
Credit Agricole's AZN Position: Q2 2026 in Review
Credit Agricole increased its AstraZeneca (AZN) stake by 24% in Q2 2026, buying an estimated $135M and bringing the position to 3,694,158 shares worth $700M. The position accounts for 1.42% of the portfolio, ranked #13.
Credit Agricole first reported a position in AZN in Q1 2014 and has held it in 31 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Credit Agricole held 3,694,158 shares of AstraZeneca worth $700M as of Q2 2026.
- Credit Agricole bought 716,592 AstraZeneca shares in Q2 2026, an estimated $135M.
- AstraZeneca made up 1.42% of Credit Agricole's portfolio in Q2 2026, its #13 holding.
- Credit Agricole first reported a position in AstraZeneca in Q1 2014 and has held it in 31 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Credit Agricole's 13F filing for Q2 2026, filed 14 Aug 2026.